Half-year report · HY
9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.7bn | 2025-07-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥23.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-07-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥36.5bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥36.1bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.0bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥29.6bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥28.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.9bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.0bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥360m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥829m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥939m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥49.53 | 2025-07-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.38 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 80.9% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2025-12-31 | ¥46m |
| Drug Substance Sales Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥8.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥7.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| Drug Substance Sales Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.3bn |
| —segment total | revenue | 2025-07-01 → 2025-12-31 | ¥13.3bn |
| —segment total | revenue external | 2025-07-01 → 2025-12-31 | ¥12.7bn |
| —segment total | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| —segment total | segment profit | 2025-07-01 → 2025-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 495
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for compensation ope cf | Prior1InterimDuration | － | JPY |
| Payments for compensation ope cf | InterimDuration | -26235000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -714368000 | JPY |
| Income taxes paid ope cf | InterimDuration | -996089000 | JPY |
| Income taxes refund ope cf | Prior1InterimDuration | － | JPY |
| Income taxes refund ope cf | InterimDuration | 5235000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 1008316000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | 360257000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1InterimDuration | -1687552000 | JPY |
| Purchase of noncurrent assets inv cf | InterimDuration | -1300073000 | JPY |
| Payments into time deposits inv cf | Prior1InterimDuration | -2649013000 | JPY |
| Payments into time deposits inv cf | InterimDuration | -181021000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1InterimDuration | 634012000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | InterimDuration | 186012000 | JPY |
| Other net inv cf | Prior1InterimDuration | -2474000 | JPY |
| Other net inv cf | InterimDuration | 1665000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -3705028000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -1293416000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -174952000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -150952000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -547234000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -673006000 | JPY |
| Other net fin cf | Prior1InterimDuration | -15686000 | JPY |
| Other net fin cf | InterimDuration | -5463000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -737872000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -829422000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -9645000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 13331000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -3444229000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -1749250000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 13195373000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 14739515000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 9751143000 | JPY |
| Cash and cash equivalents | InterimInstant | 12990265000 | JPY |
| Directors compensations sga | Prior1InterimDuration | 116799000 | JPY |
| Directors compensations sga | InterimDuration | 117768000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 282631000 | JPY |
| Salaries and allowances sga | InterimDuration | 328738000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 13312000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 13579000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 24962000 | JPY |
| Provision for bonuses sga | InterimDuration | 29574000 | JPY |
| Provision for directors retirement benefits sga | Prior1InterimDuration | 5863000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 7900000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 7408449000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 4851001000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 12259451000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 12259451000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 603822000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |